Converging lines of evidence suggest that the pathophysiology of pain is mediated to a substantial degree via allostatic neuroadaptations in reward-and stress-related brain circuits. Thus, reward deficiency (RD) represents a within-system neuroadaptation to pain-induced protracted activation of the reward circuits that leads to depletion-like hypodopaminergia, clinically manifested anhedonia, and diminished motivation for natural reinforcers. Anti-reward (AR) conversely pertains to a between-systems neuroadaptation involving over-recruitment of key limbic structures (e.g., the central and basolateral amygdala nuclei, the bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brain stem, the hippocampus and the habenula) responsible for massive outpouring of stressogenic neurochemicals (e.g., norepinephrine, corticotropin releasing factor, vasopressin, hypocretin, and substance P) giving rise to such negative affective states as anxiety, fear and depression. We propose here the Combined Reward deficiency and Anti-reward Model (CReAM), in which biopsychosocial variables modulating brain reward, motivation and stress functions can interact in a 'downward spiral' fashion to exacerbate the intensity, chronicity and comorbidities of chronic pain syndromes (i.e., pain chronification).
Introduction
Critical for the survival of organisms, pain is also a reason why lives of so many people become plainly unbearable. In addition to tremendous personal suffering, pain exerts an enormous economic toll on patients, their families and society as a whole. It is reported to afflict over 100 million Americans, costing an estimated $600 billion annually (Gaskin and Richard, 2012) due to the loss of productivity, medical expenses, and long-term disability (Institute of Medicine (IOM), 2011 http://iom.nationalacademies.org/reports/ 2011/relieving-pain-in-america-a-blueprint-for-transformingprevention-care-education-research.aspx). Over 25 million Americans experience daily pain (Nahin, 2015) . The fact that these numbers are steadily rising (Freburger et al., 2009) , in spite of the overall improving standards of health care, emphasizes the urgent need for novel insights informing better diagnosis, prevention, and treatment of pain patients.
Documented attempts to understand pain and to counteract its deleterious effects date back to the earliest accounts of written human history. Yet, the relative inefficacy of the currently available pharmacological agents (Backonja et al., 1998; McNicol et al., 2013; Skljarevski et al., 2009) , even when administered in combination (Gilron et al., 2005) , renders pain one of the most challenging problems faced by modern medicine. The International Association for the Study of Pain (IASP) defines pain as an "emotional experience associated with actual or potential tissue damage," thus pointing to affective neuroscience as promising direction for tackling this conundrum. However, while the involvement of the central nervous system in pain is well recognized, there is still a gap between remarkable basic discoveries and their translation into understanding of clinical symptomatology, and into mechanistically informed therapeutic interventions for chronic pain syndromes (defined as longer than 12 weeks duration; National Institutes of Health, 2011) .
In addition to various genetic, epigenetic (Crow et al., 2013) , and environmental factors (Shutty et al., 1992) , interpersonal variability in the engagement of emotional corticolimbic circuitry by pain may explain why some patients develop chronic pain conditions and others do not. This is supported by consistent findings of chronic painful symptoms in stress-related mood and anxiety disorders. For instance, the vast majority (up to 80%) of patients with Major Depressive Disorder (MDD) reports comorbid pain conditions (Leuchter et al., 2010) . Additionally, pre-surgical pain catastrophizing scores have been shown to predict the severity of chronic post-surgical pain (Havakeshian and Mannion, 2013) whilst the evolution of chronic pain depends, in part, on the propensity toward repeated engagement of corticolimbic stress and reward circuits Baliki et al., 2012) .
Here we discuss the role of neuropathological entities known as 'reward deficiency' (RD) and "anti-reward" (AR), clinically evident in respectively decreased sensitivity to natural reinforcers and in stress-like negative affective states as valid components of chronic pain. Chronic pain appears to impact both hedonic and aversion related behaviors so that rewarding stimuli become less rewarding, and aversive stimuli become more aversive. A parallel may be drawn to drug dependence, where patients over time lose the initial "high" of a stimulant, and eventually "need drugs just to be normal", but such 'normality' may become hard to bear due to increased stress (Volkow et al., 2016) . Similarly, in persistent pain, the rewarding properties of pain relief may diminish over time and the averseness of uncontrolled pain and negative events becomes more and more overwhelming (Elman and Borsook, 2016; Elman et al., 2011) . These processes interact with and are affected by functions in so called 'classic pain circuitry' in the central nervous system; regions involved in pain processing include somatosensory (e.g., thalamus, primary somatosensory cortex, posterior insula cortex), emotional (e.g., cingulate, basal ganglia, amygdala, hippocampus) and descending modulatory control (e.g., periaqueductal gray) systems.
Chronic pain might be operationalized in distinct ways; however, the present approach offers several advantages. First, it has defined neuroanatomical and neurofunctional components (Blum et al., 2012b; Elman et al., 2013) . Second, it rests on firm clinical research grounds i.e., RD and AR are involved in the centralization of pain (See Box 1 for definition) which is theorized to play a key role and contribute to comorbid aberrant emotional and cognitive processing Bushnell et al., 2013; Elman et al., 2013) . Third, it attempts to model the unremitting course of chronic pain that renders the innate homeostatic and pharmacological analgesic processes ineffective, leading to impairments in normative compensatory mechanisms and shifting the set point for the hedonic and sensory homeostasis towards the development of refractory pain conditions accompanied by persistently negative affective states (Elman et al., 2013) .
The following text is divided into four sections containing: (1) a brief summary of Pain and Reward Neurobiology; (2) Neuroanatomical and clinical manifestations of Reward Deficiency (RD) and Anti-reward (AR) States in Chronic Pain along with the role of (3) General Model of RD-AR in Pain Centralization/Chronification (see Fig. 1 ) and in its comorbidities; we have termed this model Combined Reward Deficiency Antireward Model (CReAM) for chronic pain; and finally (4) Treatment Opportunities in CReAM, where the focus rests on the pharmacological, brain modulation and psychological therapies informed by CReAM.
Pain and reward neurobiology
Any attempt to enhance our understanding regarding the brain mechanisms underlying the transformation from health to chronic pain faces a major challenge: how to operationalize such a commonplace condition that has been given as many explanations as there are treatises that have dealt with it. The concept of a pain connectome has recently emerged to encompass the multitude of brain connections that constitute an altered state in chronic pain (Kucyi and Davis, 2015) . However, constraining such a connectome to some core networks has proven difficult, as the human experience of pain can engage and modulate everything from basic sensory perceptions to manifestations of culture (Elman and Borsook, 2016) . In a clinical context, some examples include the role Box 1: Definition of terms.
Allostasis: attaining temporal stability in response to challenge via supraphysiological changes in systems that normally promote homeostasis (McEwen and Stellar, 1993) .
Allostatic load: the burden on the system with the consequent 'wear and tear' as a result of repeated and/or dysregulated allostatic changes that acutely support an attempt for stabilization of regular function (McEwen and Stellar, 1993) .
Anti-reward: a condition wherein interference with homeostatic functioning of the reward and reinforcement circuitry due to recurrent stimulation by drugs and/or by pain triggers between-system adaptation, recruiting central and basolateral amygdala nuclei, the bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brain stem, the hippocampus and the Hb that in concert contribute to massive outpouring of stressogenic corticotropin-releasing factor, norepinephrine and dynorphin. This is manifested in negative affective states, anhedonia and motivational states that are rigidly and exclusively focused on seeking drugs or on the relief of pain.
Centralization of pain: the process by which the initial pain (e.g., injury) transforms to chronic pain with complex comorbid changes including altered psychological status (anxiety, depression), addiction, altered reward and antireward function (see Borsook et al., 2013c) .
Central sensitization of pain: as a result of a nociceptive barrage, changes in sensitivity of the central pain/nociceptive pathways may result in a prolonged and usually reversible increased in excitability to stimuli resulting in clinical manifestations of hypersensitivity (viz., dynamic tactile allodynia, secondary punctate or pressure hyperalgesia, after-sensations, and enhanced temporal summation) (Woolf, 2011) .
Cross sensitization: a state when prior exposure to one stimulus (i.e., pain) increases subsequent response to a different stimulus (e.g., stress, drugs, allergies or smell) and in the reversed order, e.g., enhancement of pain following prior stress exposure.
Denervation hypersensitivity: this is the state of supersensitive/enhanced response to a signal/neurotransmitter as a result of an interrupted synaptic (input/receptor) activation or function.
Feed-forward interaction: contrary to the negative feedback concept, positive feedback is an autonomous, self-sustaining feed-forward loop wherein whereby a stimulus mounts escalating responses that are amplifying the original stimulus.
Habituation: the term is used to denote a decrease in a behavioral or physiological response to a repeated stimulus (e.g., drug, painful).
Hedonic tone: the amount of pleasurable or positive feelings a person experiences at a given time point. Homeostasis: in the context used here, it is the maintenance of a physiological equilibrium of the internal environment or function in the face of external changes (e.g., stress, drugs etc).
Intervening variable: a subjective state that connects physiological necessities with motivations and ensuing behaviors. Motivational/incentive salience: a "wanting" process by which an organism determines the motivational value of a particular object beyond the emotional experience it evokes i.e., "liking."
Opponent-proponent systems: a situation when a stimulus or an affective (i.e., proponent) process evokes an affective (opponent) process of the reversed valence. The latter may be particularly apparent with the cessation of the former (e.g., a sense of euphoria ensuing with termination of pain).
Pain: an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (IASP; http://www.iasp-pain.org). Pain is considered to be a chronic condition when it lasts longer than 3 months.
Pain chronification: the process of maintenance of ongoing pain that may increase in severity over time. The process may include increased levels of depression or anxiety that contribute to maintenance or severity of pain.
Phasic and tonic dopamine release: tonic dopaminergic neurotransmission refers to the sustained release of dopamine due to ongoing, background of neuronal activity whereas phasic dopaminergic transmission refers to the sudden release of dopamine due to transient, spontaneous bursts of neuronal firing, usually in response to a stimulus or an event (Grace, 1991 (Grace, , 1995 Jarcho et al., 2012) . Tonic firing refers to spontaneously occurring baseline spike activity. Phasic activation of the DA system involves a burst-spike firing pattern and is dependent on glutamatergic excitatory synaptic drive onto DA neurons. Burst spike firing triggers a high amplitude, transient, phasic DA release intrasynaptically within the targeted areas (Floresco et al., 2003; Grace, 1995) .
Primary and secondary hypodopaminergia: decreased dopamine levels due to an innate biological process/disease (primary) or as a result of exogenous factors (secondary).
Pseudo-addiction: the term describes drug-seeking behavior that occurs in a pain dependent manner (i.e., patients may have inadequate pain treatment).
Reward-aversion continuum: the ongoing subjective evaluation of pleasurable/rewarding and aversive processes; in the context of pain it refers to pain relief (rewarding) vs. pain onset/presence/persistence (i.e., pain vs. analgesia).
Reinforcement: an increase in a likelihood of repeated action. In a biological context, rewards are associated with survival of individual and species (e.g., obtaining food, water and sex).
Reward: any stimulus that is perceived as positive or pleasurable (Hyman and Malenka, 2001) . Reward-deficiency: diminution in the capacity to experience joy and pleasure along with paucity of drive and motivation arising in the context of hypofunctionality of the brain circuits mediating reward, reinforcement and motivation (Comings and Blum, 2000; Elman et al., 2009) . The reward deficiency state may have a genetic antecedent expressed in the dopamine D2 receptor polymorphisms (Blum et al., 2013) rendering susceptible individuals to baseline or easily acquired reward deficiency. Chronic pain may result in alterations in the reward cascade with subsequent increase in discomfort and inability to garner good feelings from normally rewarding stimuli. The hallmarks of such maladaptations include anhedonia, numbing, apathy and decreased motivation for natural reinforcers.
Reward and reinforcement circuitry: comprised of an 'in-series' pathway linking the ventral tegmental area, NAc and ventral pallidum via the medial forebrain bundle (Gardner, 2011) .
Sensitization: pain-induced changes in the mesolimbic dopaminergic circuitry including dopamine terminal fields (e.g., striatum, amygdala, and mPFC) underlying normal opponent and proponent processes that transform these processes into heightened incentive salience assigned to pain, analgesia and to related cues.
of expectations and physician-patient interaction in placebo and nocebo responses (Carlino and Benedetti, 2016) , or the intrinsically rewarding properties of pain relief (Becerra et al., 2001; Navratilova et al., 2015) . The figure is a schematic overview of the chronic pain's self-sustaining and progressively worsening nature. Acute pain activates dopamine transmission in the brain's reward and motivational centers, whereas prolonged periods of pain produce the opposite effect (within system adaptation) clinically manifested by anhedonia and diminished motivational/incentive salience of natural reinforcers, that is to say the Reward Deficiency State (RD). Allostatic adjustment (processes that attempt to normalize the stress on the system) to excessive dopaminergic trafficking in response to recurrent pain leads to a between system adaption involving the central and basolateral amygdala nuclei, the bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brain stem, the hippocampus and the Hb that in concert contribute to massive surges of CRF, norepinephrine, glutamate and dynorphin leading to the Anti-Reward State (AR) (see text). Thus, recurrent pain or ongoing pain may contribute surges of these stress-related chemicals. While stressogenic CRF and norepinephrine influx contribute to the subjective sense of stress and similar negative affective states and dynorphin further worsens the anhedonia associated with the RD, glutamatergic sensitization promotes overlearning of the motivational salience of pain, analgesia and cues that predict the onset or severity of pain so that pain is constantly perceived to be worse than expected (viz., catastrophizing). These effects result in an unstable positive feedback loop wherein the combined reward RD and AR model (CReAM) drives further enhancement of pain and thus contributes to progressive worsening of the clinical condition and the buildup of the allostatic load that is unchecked by physiological negative feedback mechanisms leading to a diseased condition of the brain to the point of end-stage outcomes of chronic pain (i.e., intractability). (+) Signs represent stimulation.
The reward-aversion continuum
Dopaminergic neurons in the ventral tegmental area (VTA) and their projections into the Nucleus Accumbens (NAc) comprise a putative 'homeostat' (Goldstein and McEwen, 2002 ) that compares hedonic information with a pre-set point. Specifically, reward signals in the brain motivate actions that increase the probability that the behavior will be repeated in the future, whereas aversive signals inhibit actions that are likely to result in fruitless pursuits or in painful consequences (Wickens, 2008) . The opponent-process theory (OPT) of emotion postulates that hedonic tone is derived from valuationally opposite reward and aversion processes Corbit, 1973, 1974) mediating hedonic homeostasis viz., equilibrium of emotional and motivational states. For example, evocation of fear may in turn contribute to positive emotions as is the case for roller coasters, automobile racing, skydiving and horror movies or 'traumatic bonding' developed by victims toward their tormentors i.e., "Stockholm syndrome." (Cantor and Price, 2007) .
Pain and reward are opponent processes (Becker et al., 2012) , but the latter is usually eclipsed by the former, so that the sense of euphoria only becomes noticeable with the cessation of a painful condition. The inter-subject variability regarding the proponentopponent processes interactions may be quite substantial, and a reverse situation is also possible. For example, in the extreme case of algophilia, pain can be experienced as pleasant. Masochistic and/or sadomasochistic behaviors occur with some frequency in the population and are associated with generally adaptable psychosocial functioning. Conversely, self-mutilating acts in patients with borderline personality disorder, trichotillomania and excoriation disorder (American Psychiatric Association, 2013) highlight the fact that pain and pleasure are not only opposites on a continuum, but may also be properties of a hedonic pain control system with negative feedback processes.
A key feature of the OPT is that repeated activation of one process results in a progressive weakening of that process and strengthening of the opponent process. Based on this concept, Koob and colleagues advanced a model of the neurobiological basis of addiction that emphasizes the close interface between the reward and Reward and anti-reward neurobiological systems are formed from hierarchically organized corticolimbic regions along with the clusters of hypothalamic and brainstem nuclei. The central nodes in the respective systems, namely the nucleus accumbens (NAc) and the Hb also constitute their major interface. The meso-accumbens dopamine pathway, extending from the ventral tegmentum (VT) of the midbrain to the forebrain regions such as the NAc, amygdala and medial prefrontal cortex (mPFC), is the crucial component of the brain reward and reinforcement system that purportedly mediates in the maintenance of hedonic homeostasis. The habenula, an epithalamic nucleus with projections from the spinothalamic tract and to the periaqueductal gray matter (PAG), is a brain region with integrated sensory, emotional and motivational functions that modulates pain intensity, aversion and motor responses. Increased dopamine neurotransmission from the ventral tegmentum to the NAc is associated with euphorogenic responses to both natural rewards and to drugs of abuse. The habenula, on the other hand, opposes this action by providing inhibitory tone to dopamine neurons (with the input from other areas of the corticolimbic limbic system and basal ganglia) via interpeduncular and rostromedial tegmental nuclei projections, resulting in decreased dopamine transmission in the NAc and in the medial prefrontal cortex (mPFC), clinically visible as decreased motivation and anhedonia. The functional reciprocity between NAc and Hb is also evident in the increase of the latter's firing to absence of an expected reward or to predictors of no-reward and the decrease of their firing when an expected reward occurs. Recurrent dopaminergic trafficking consequent to pain eventually results in hypodopaminergic reward deficiency state in the NAc and in the mPFC and eventually gives rise to the between-system anti-reward adaptation, recruiting the Hb along with the central and basolateral amygdala nuclei, the bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brainstem, the hypothalamic supraoptic nucleus and the hippocampus that in concert contribute to massive outpouring of stressogenic corticotropin releasing factor (CRF), norepinephrine and dynorphin manifested in negative affective states, anhedonia and enhanced motivational salience attributed to pain and to relevant cues. Other major neurotransmitter systems contributing to aversive anti-reward states including serotonin and acetylcholine are regulated by the Hb via respective raphe nuclei, locus coeruleus and nucleus of Meynert. Thus, the NAc and Hb are involved in reinforcement and are interconnected with the major brain regions involved in the modulation of pain, stress and emotions. As such, down regulation of reward circuitry in conjunction with sensitization of anti-reward structures contributes to the transition from the controlled pain situation to intractable and escalating painful states accompanied by emotional anguish. Bottom: connectivity Maps for the Accumbens and for the Habenula. Reward and anti-reward circuitry has been examined recently through human neuroimaging experiments. As this literature grows, it has become increasingly possible to use "big data" methods such as text-mining, meta-analysis and machine-learning techniques to aggregate and synthesize neuroimaging findings (Yarkoni et al., 2011) . These methods provide a convenient way to illustrate and decode brain states as shown for the two model structures below. Nucleus accumbens: automated Neurosynth meta-analysis of 329 studies of the feature "reward". Lexigraphical features for NAc (MNI ± 10, 8, −10) include reward, rewards, money, incentive, and addiction. The meta-analysis was performed by automatically identifying all studies in the Neurosynth database that loaded highly on the feature "reward", and then performing meta-analyses to identify brain regions that were consistently or preferentially reported in the tables of those studies (see http://neurosynth. org/) (Yarkoni et al., 2011) . Habenula: functional co-activation map of 140 studies, and top lexigraphical features for Hb (MNI ± 4, −24, 2): monitoring, incentive, sadness, anticipation, disgust, and no-go. Note, not enough studies have investigated anti-reward to produce an automated meta-analysis. Instead, we investigated what regions co-activate with the Hb, and what features are commonly associated with activation of the Hb region (Yarkoni et al., 2011). stress systems (Koob et al., 2014; Koob and Le Moal, 2005) . The authors proposed that repeated drug-taking produces a decreased functioning of the reward systems, combined with a strengthening of the so-called "anti-reward" systems that subserve the opponent process of aversion. The former's dysfunction is characterized by a diminished capacity to experience joy, pleasure and motivation (i.e., RD), whereas the latter manifests as the subjective experience of aversion and stress (i.e., AR). The focus of this article is to argue that the combined RD-AR state, initially proposed as a model of addiction, is also relevant for understanding chronic pain. This relevance is supported by the key role of these processes in the experience of emotional pain (Koob et al., 2014) and the current recognition that physical and emotional pain connote anatomically overlapping and functionally congruent entities (Eisenberger, 2012) .
Brain circuitry of reward, aversion, and the RD-AR state in addiction
Knowledge of the human reward-and anti-reward circuitry comes in part from extensive investigations of rodent and primate models (Haber and Knutson, 2010; Hong et al., 2011; O'Doherty, 2004; Thomas et al., 2001) . While a major focus has been on the circuitry projecting from the VTA to the NAc (Russo and Nestler, 2013) , other brain regions e.g., amygdala and medial prefrontal cortex (mPFC) that are connected to these two structures are also involved, (Oades and Halliday, 1987; Salgado and Kaplitt, 2015; van Domburg and ten Donkelaar, 1991) . Although the periaqueductal gray (PAG) that is involved in a number of behaviors (Linnman et al., 2012) including pain modulation, is not classically part of reward circuitry, it is connected to many regions of the brain involved in reward including the NAc (Ikemoto, 2010) .
The NAc and habenula (Hb) are two respective nodes with discrete functions related to reward and aversion. The habenula, located above the posterior thalamus, is divided into medial (MHb) and lateral (LHb) portions, and is primarily responsible for conveying information from the limbic forebrain to the limbic midbrain areas (Sutherland, 1982) . The NAc, part of the ventral striatum, is a critical element of the mesocorticolimbic system, a brain circuit implicated in reward, motivation, and salience attribution (Borsook et al., 2013b) . Recent optogenetic studies have shown that NAc and LHb participate in distinct dopaminergic circuits for eliciting reward and aversion, respectively: a reward circuit from the laterodorsal tegmentum to dopaminergic neurons in the VTA that project to the NAc, and an aversion circuit in which the LHb inhibits dopaminergic neurons in the VTA that project to the medial PFC (Lammel et al., 2012) . This provides a potential neuroanatomical model integrating reward (dopaminergic drive) and aversion (dopaminergic inhibition).
A number of studies have suggested that the Hb conveys an aversive or 'anti-reward' signal (Stopper and Floresco, 2014) , is involved in negative prediction error processing (Salas et al., 2010) , and in a number of aversive states (Hennigan et al., 2015; Meye et al., 2015; Zuo et al., 2015) . An inhibitory function may be related to the integration of reward expectancy, reward, or punishment as noted in a functional magnetic resonance imaging study (fMRI) study of the human Hb (Ullsperger and von Cramon, 2003) . Both MHb and LHb neurons are excited by aversive stimuli or by the omission of an expected reward (Hikosaka, 2010) . LHb inactivation abolishes choice biases, making rats indifferent when choosing between rewards associated with different subjective costs and magnitudes, but not larger or smaller rewards of equal cost (Stopper and Floresco, 2014) . NAc activity is related to reward prediction error, in that it encodes the discrepancy between expected and actual reward outcome (Abler et al., 2006) . Notably, altered neural processing of prediction error is associated with a number of neurological and psychiatric diseases (Borsook et al., 2013a; Klein et al., 2013) , including chronic pain (Baliki et al., 2010) .
Neurons from the LHb send indirect negative feedback signals to dopamine cells in midbrain regions including the VTA via the rostromedial mesopontine tegmental nucleus also (Balcita-Pedicino et al., 2011) . Thus, stimulation of the habenula leads to inhibition of dopamine release in neurons in the VTA (Omelchenko et al., 2009 ) and substantia nigra (Christoph et al., 1986) . Specifically, LHb neurons act on GABAergic neurons that inhibit dopamine release (Barrot et al., 2012 ) thus pointing to this structure's important role in adapting or responding to rewarding or stressful stimuli. Therefore, a higher engagement of the Hb reduces the probability of phasic dopamine release in the reward system.
Reward circuitry and the RD state
A key brain mechanism of the rewarding effects of both natural reinforcers as well as drugs of abuse is the increase in NAc dopamine levels (Carlezon and Thomas, 2009 ). The intervening variable (see Box 1 for definition) of subjective pleasure is sensed in the mPFC (Berridge and Kringelbach, 2013; Goldstein and Volkow, 2002 ) that exerts top down control of dopaminergic activity in the NAc via the cortico-striatal segment of the cortico-striato-thalamo-cortical circuit (Bimpisidis et al., 2013; Volkow et al., 2011) . Increases or decreases in the NAc's dopamine concentrations prompt respective habituation (Di Chiara et al., 2004) or sensitization (see definition in Box 1) (Tremblay et al., 2002) in the key effector systems consisting of pre-and post-synaptic dopamine receptors. Presynaptic dopamine transporters and enzymes involved in dopamine's synthesis and metabolism oppose and thereby balance abrupt dopaminergic changes.
A reduction in dopamine levels, or hypodopaminergia, within brain circuits mediating reward and motivation is the fundamental neurobiological change that underlies the RD state. This hypodopaminergia may be innate (primary) or acquired (secondary, e.g., drug-induced). As noted above, this state is clinically noticeable as a blunted capacity to enjoy or to experience pleasure along with decreased motivation for natural rewards (Comings and Blum, 2000; Volkow et al., 1997; Wise et al., 1978) including various activities that are driven by sociability, enthusiasm, esthetic awareness, altruism and self-fulfillment.
Aversion/stress circuitry and the AR state
Regions involved in aversion and stress responses include the central and basolateral amygdala nuclei, the bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brainstem, the hippocampus, and the Hb. The heightened sensitivity of the aversion system that characterizes the AR state in addiction is generated via massive surges of corticotropin-releasing factor (CRF), norepinephrine, glutamate and dynorphin. The stressogenic CRF and norepinephrine release contribute to the subjective sense of stress and related negative affective states (e.g., fear, anxiety and depression) while dynorphin further worsens the anhedonia associated with the RD (Nestler and Carlezon, 2006) . AR disrupts the normal function of brain areas involved in reward/motivation and stress processing, thereby reducing the impact of rewarding stimulation and the ability to restrain stress responses. Although the AR state may possess some heuristic value in dissuading an individual from engagement in hazardous situations (Henchoz et al., 2013) , the generated allostatic load is clearly dysfunctional as it promotes isolation and social withdrawal, jeopardizing adequate coping and adjustment.
As part of AR processes, initial homeostatic adjustments to diminished tonic, resting state dopaminergic neurotransmission in the NAc and prefrontal cortex produced by addictive drugs results in robust augmentations of phasic dopamine responses to stress and, via Pavlovian conditioning, to the relevant cues (Kalivas and Volkow, 2011; Volkow et al., 2011) and/or to interoceptive bodily states (Verdejo-Garcia et al., 2012) . Prefrontal activations caused by these cues profoundly increase PFC glutamatergic output (Kalivas and Volkow, 2005) to an already hypofunctional NAc (Kalivas and Volkow, 2005) , thus further decreasing dopaminergic activity with consequent worsening of the RD.
The progressive RD-AR adaptation is metaphorically termed the "dark side of addiction" (Koob and Le Moal, 2005) as it is unchecked by physiological negative feedback mechanisms, with drugs (and/or natural rewards) providing only transient symptomatic relief while worsening neuroadaptations. It may be quite difficult to stop and/or reverse the developed vicious cycle as opioid analgesic drugs further worsen the RD and cause hyperalgesia to the point of systematic collapse (Apkarian et al., 2004; Goldstein and Volkow, 2011) and subsequent end-stage outcomes such as suicide (Fishbain, 1999; Gilbert et al., 2009 ).
Notwithstanding some negative affective states that may be jointly induced by RD and AR via hypodopaminergia and dynorphin, there are important differences between these neuroadaptations, including neuroanatomical, neurochemical and key clinical manifestations (see Table 1 ). For instance, RD and AR jointly contribute to negative affective states through dynorphin which in turn modulates RD. On the other hand, other aspects of negative affective states such as anxiety or stress are mostly contributed by stressogenic hormones (CRF and norepinephrine).
The RD-AR state in chronic pain

Chronic pain and RD/hypodopaminergia
Patients with chronic pain exhibit certain psychopathological and clinical features in common with addiction. Both pain (Wood, 2008; Wood et al., 2007) and opioids (Tanda et al., 1997) activate dopamine transmission in the brain reward circuitry, including the NAc, whereas prolonged periods of pain or opioid drug consumption produce the opposite effect (Wiech and Tracey, 2013) viz., RD (Assogna et al., 2011) . Activation of mesolimbic reward circuitry, including the NAc, occurs with both acute pain and pain relief Navratilova et al., 2012) ; the latter may reflect the evocation of the opponent process.
Evidence supporting a hypodopaminergic state in chronic pain comes from both preclinical (Niikura et al., 2010) and clinical (Hipolito et al., 2015; Kasahara et al., 2011; Loggia et al., 2014; McDougle et al., 2015) data. Pain syndromes that have shown altered dopaminergic processing include burning mouth syndrome (Hagelberg et al., 2003) , atypical facial pain (Hagelberg et al., 2003) , and fibromyalgia (Wood et al., 2007) . For example, in fibromyalgia patients vs. healthy pain-free controls a marked blunting in striatal dopamine release was evident following induction of experimental pain (Wood et al., 2007 17610577) . The high incidence of central pain (including neuropathic pain) in Parkinson's patients (Canavero, 2009; Defazio et al., 2008) suggests that pain is a common symptom in patients with hypofunctional nigrostriatal dopaminergic pathways (Coon and Laughlin, 2012) , and that low dopamine may contribute to increased pain (Wood, 2008) . Even among seemingly healthy individuals, low dopamine receptor availability is associated with enhanced pain responses (Pertovaara et al., 2004) . Specific polymorphisms in the dopamine transporter gene (DAT-1) convey a high pain sensitivity stemming from a hypofunctional dopaminergic system (Treister et al., 2009 ). In healthy human volunteers, dopamine depletion (i.e., primary or secondary hypodopaminergia − see Box 1) influences pain affect and not sensory aspects of acute painful stimuli (Tiemann et al., 2014) , supporting the idea that in chronic pain, hypodopaminergia targets changes in affective states contributing to centralization of pain. Hence, whereas in healthy individuals low dopamine (primary or secondary, see Box 1) is associated with enhanced pain sensitivity, chronic pain may further decrease dopaminergic activity through a feed-forward interaction (i.e., positive feedback; see Box 1) compromising both sensory and affective/cognitive processes (Jarcho et al., 2012) . In addition, dopamine is involved in descending inhibitory modulation of pain transmission, which is an additional link between hypodopaminergia and chronic pain (Potvin et al., 2009) .
Decreased levels of tonic dopamine result in increased sensitivity of remaining dopamine neurons (Grace, 1991; Pucak and Grace, 1991) and heightened phasic dopamine release. The diminished dopaminergic tone contributes to the increased sensitivity of pain patients to emotional stimuli, somewhat similar to the phenomenon of denervation hypersensitivity (see Box 1 for definition).
Chronic pain and AR/stress
The recruitment of stress and emotional systems as a result of excessive activation of the reward system in response to recurrent pain may lead not only to low detection capability for natural rewards within the dopaminergic system (i.e., RD) but also to a between-system adaption of heightened sensitivity to aversion and stress, viz., the AR state. There are several lines of evidence that link chronic pain to AR. On the psychophysiological level, AR in pain patients is evident via their hypersensitive responses to conditioned stressful stimuli (Marcinkiewcz et al., 2009; Miguez et al., 2014) . Clinically, stress is an integral part of the chronic pain syndrome (McEwen and Kalia, 2010; Neeck and Crofford, 2000) . Pain patients exhibit heightened levels of stress and arousal (Thieme et al., 2006) and stress also plays a key role in exacerbations of pain symptomatology (Finan and Smith, 2013; Lauche et al., 2013) . Furthermore, an exaggerated sympatho-adrenal tone as evidenced by increased heart rate (Chalaye et al., 2013) , norepinephrine concentrations (Buscher et al., 2010) (Buvanendran et al., 2012) , and skin conductance (Bonnet and Naveteur, 2004) are frequent clinical findings in chronic pain patients (Currie and Wang, 2004) . Also, the CRF receptor type 1 is implicated in visceral hyperalgesia (Larauche et al., 2012) , while heightened CRF cerebrospinal fluid concentrations tend to parallel both sensory and affective pain components (McLean et al., 2006) .
Reward/aversion circuitry of NAc and Hb: role in chronic pain
Stimulation of the Hb has been reported to produce analgesia in a model of acute pain, the formalin test (Cohen and Melzack, 1986) . However, we are unaware of similar studies in a chronic pain model, and a pain inhibitory effect would be difficult to interpret within the context of a role in AR. Indeed, the literature is far from unambiguous on this account and is still evolving. In fMRI studies, this brain region is activated by acute pain in healthy volunteers (Shelton et al., 2012) and is tonically activated in patients with chronic pain (Erpelding et al., 2013) . Importantly, pain-induced alterations in functional connectivity of the Hb improve with analgesic therapy, suggesting that resolution of chronic pain improves Hb's communication with the frontal and brainstem limbic regions (Shelton et al., 2012) . Functional imaging in central pain thalamic stroke patients implicated Hb lesions in the onset and exacerbation of chronic pain (Sprenger et al., 2012) . Both animal (Li et al., 1993; Xie et al., 1998) and human (Shelton et al., 2012) studies have shown connections between the Hb and the PAG, a region involved in pain modulation (Basbaum and Fields, 1979) . Efferent projections from the LHb may involve a pathway to the dorsal reticular nuclei and activation of this pathway may produce inhibition of avoidance or escape perfor- (Pobbe and Zangrossi, 2010) . Activation of the NAc has been observed with both acute (Becerra et al., 2001 ) and chronic pain. A significant role for the region in chronic pain has subsequently emerged in human imaging studies (Baliki et al., 2010) , including studies suggesting a role in altered sensory processing (e.g., allodynia (Ren et al., 2016) ) in chronic pain, and, more importantly, in predicting pain chronification (Baliki et al., 2012) . In an animal model of postsurgical pain, pain relief seems to produce activation of dopamine neurons in the VTA and to increase dopamine release in the NAc (Navratilova et al., 2012) . In addition, activation of mesolimbic dopamine neurons in the VTA that project to the NAc, plays an important role in mediating the suppression of tonic pain (Altier and Stewart, 1999) . LHb stimulation inhibits dopamine neurons (Ji and Shepard, 2007) . The interactions between the reward and antireward networks (central nodes in NAc and Hb, respectively) are likely the reason why deep brain stimulation (DBS) in the treatment of resistant depression appears to be effective both when electrodes are placed in the NAc as well as when placed in the Hb (Schlaepfer and Bewernick, 2013) . Fig. 2 is a summary of interactions between the NAc and Hb and connections between these regions and others in the brain based on Functional Connectivity Mapping.
The above two structures do not exist in isolation. They are rather embedded within a complex network of interrelated systems, each of which exhibits a unique function within the context of chronic pain. For instance, a decrease in dopamine activity (i.e., hypodopaminergia) underlying RD can promote an AR state via potentiation of glutamatergic neurotransmission (Kalivas and Volkow, 2005) . In support of this notion, the administration of neuroleptics can produce an aversive state in human patients (Bruun, 1988; Naber, 1995) . Furthermore, animal research indicates that the inhibition of the dopamine system through pharmacological or optogenetic means induces aversion and anxiety (Ilango et al., 2014; Liu et al., 2008; Sanberg, 1989) . Electrophysiological studies report decrease in punishment during phasic suppression of firing in dopamine neurons (Schultz et al., 1997) . Thus, reduced dopamine activity may produce both RD and AR states, which evoke additional interactions with other brain systems and/or with each other in a 'downward spiral' manner to exacerbate chronic pain.
General model of RD-AR in pain centralization/chronification
The general conceptual model is schematically outlined in Fig. 3 and summarized in Table 2 . Chronic pain disrupts the normal function of the structures involved in stress and reward, defining two interrelated patterns of brain alterations, namely RD and AR. These changes may be complemented by genetic, epigenetic or disease status, and contribute to the 'failed state' of brain function in chronic pain, adding to the severity of comorbidities and pain chronification (see Box 1). We have previously termed such changes as the centralization of pain (Borsook et al., 2013c ) (see below). Here, we suggest that the combination of alterations in the normal function of Reward and Anti-Reward brain systems provides the basis for pain centralization (see Box 1). Below we integrate concepts based on these systems, including interactions between RD and AR function, and provide clinical examples of comorbid conditions (i.e., addiction, depression) or innate differences in hedonic tone that may either be exacerbated by pain centralization, or that may exacerbate pain centralization on the basis of CReAM (see Fig. 4 ).
Pain and addiction
Cross sensitizing drugs (Cunningham and Kelley, 1992) may be a mechanism involved in the complex interactions of chronic pain and opioid-induced increases in pain i.e., opioid-induced hyperalgesia (Angst and Clark, 2006) or the chronification of pain with opioid use as exemplified in migraine (Bigal and Lipton, 2009 ). The concept of cross-sensitization described in the addiction literature typically refers to a situation where prior exposure to one stimulus (e.g., drug) increases subsequent response to itself (Angrist and Gershon, 1970; Post et al., 1982; Satel et al., 1991; Strakowski et al., 1996) , and to a different stimulus e.g., stress; (Goeders, 2003; Southwick et al., 1999; Yehuda and Antelman, 1993) . The reverse can also occur, that is the enhancement of drug (Antelman et al., 1980; Sorg and Kalivas, 1991) and stress effects (Goeders, 2003; Southwick et al., 1999; Yehuda and Antelman, 1993) following prior stress exposure. The sensitized stress responses in chronic pain may thus confer greater motivational salience to pain-related cues, i.e., cross-sensitization (Rome and Rome, 2000) , and thus may increase opioid analgesic drug consumption, which further increases stress and consequently enhances cue responsivity and an ensuing transition from an excessive drug intake to a bona fide addiction.
Although it is hypothesized that addiction develops via negative reinforcement mechanisms viz., the drug is used to ameliorate the averseness of pain and of accompanying negative emotional states (Khantzian, 1997) , we propose an adaptation of this idea in the form of a positive reinforcement hypothesis i.e., reward deficiency and anti-reward processes enhance drug use through amplification of its rewarding and reinforcing properties (Elman (Tsai et al., 1995) Mediation of PFC-amygdala interactions during stress-like i.e., AR responses (Mora et al., 2012) Altered tonic/phasic dopamine/ glutamate interaction is caused by chronic pain
Memory of reward-action association Antagonism of glutamate produces reward-like effects (Krystal et al., 1998) Glutamate is implicated in depression, PTSD and in other stress-related conditions (Dunlop et al., 2012; Hasselmann, 2014) Overlearning of the motivational significance of cues that predict the onset or severity of pain so that pain is constantly perceived to be worse than expected i.e., catastrophizing. Dynorphin decreases dopamine release (Krebs et al., 1994) Descending pain control; analgesia
Addiction to opioid analgesics
Dynorphin elicits stress-like, AR symptoms (Berke and Hyman, 2000) Excessive opioid drugs' synergism with pain in creation CReAM (see Fig. 2) The habenula, central & basolateral amygdala nuclei, the bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brainstem, the hippocampus raphe nuclei, locus coeruleus & nucleus of Meynert (Elman et al., 2013) CRF, norepinephrine, dynorphin, serotonin and acetylcholine
Habenula inhibits activity of mesolimbic dopaminergic neurons
Up-regulation in the limbic structures secreting CRF, norepinephrine & other hormones
Potential utility of not yet approved adrenergic, kappa and CRF antagonists for pain management AR processes enhance drug use through amplification of its rewarding and reinforcing properties (Elman et al., 2002) Negative affective states Pain-related fear, anxiety and depression Fig. 3 . Progression from homeostasis to allostatic load and the spiraling distress cycle. Schematic diagram of potential mechanisms involved in the development of CReAM (RD + AR) in chronic pain patients. Pain disrupts the normal homeostatic function of the structures involved in reward and aversion/stress processing thereby giving rise to potential competitive, independent (i.e., additive) or synergistic types of interactions. For acute or mild pain competition may be the most notable one because opponent processes contribute to the self-limited nature by restoring the homeostatic equilibrium.
With ongoing pain, analgesics may be less effective and the counterbalance in the adaptive state is lost. In addition, because allostatic changes, reflected in the use of analgesic agents, occur even when the treatment of pain is deemed adequate, the resultant allostatic load may be additive with that of the chronic pain (e.g., drive drug dose escalations). Synergism may occur when the recursive partly shared positive feedback CReAM loops are produced by both chronic pain and potentially by the analgesics themselves (Upadhyay et al., 2010) resulting in a "spiraling distress cycle" whereby there is an amplification of the aversive physical and emotional aspects of pain. Such processes may further contribute to treatment resistance (to current pharmacotherapies) in chronic pain. et al., 2002) . This results in an autonomous, self-sustaining feedforward loop whereby trivial pain or stress can mount escalating dopamine release in the striatum, priming catastrophizing and further escalating the "spiraling distress cycle" of chronic pain similar to addiction (Koob and Le Moal, 1997) This triggers the drive to seek and consume drugs (i.e., craving), leading to secondary drug-induced phasic dopaminergic bombardment (Grace, 2000) that eventually overpowers the homeostatic restraint (Koob and Le Moal, 2001 ) and gives rise to the CReAM. It is also plausible that acute administration of opioid analgesic drugs in chronic pain patients alleviates emotional numbing temporarily by boosting the activity of the reward regions (Jakupcak et al., 2010) while regular or habitual consumption leads to further reward circuitry desensitization clinically manifested as emotional numbing (Volkow et al., 2007; Wang et al., 2012) . Consequently, chronic pain may become unbearable not only on a physical level but also on a psychosocial level. Patients must cope with debilitating pain and the associated stress it brings, to the point of developing pseudo-addiction i.e., compulsive seeking of opioid drugs driven by the desire to try to ameliorate inadequately treated pain or to avoid a feared opioid withdrawal (see Box 1); the term thus describes drug-seeking behavior that occurs in a pain-dependent manner, as an active coping strategy to alleviate undertreated pain, and is fully reversible. It is therefore distinguishable from the construct of addiction, which by definition is compulsory, maladaptive and hedonistic in nature (Weissman and Haddox, 1989) , and from and pseudo-opioid resistance (selfreported pain despite adequate analgesia owing to unwarranted anxiety about a feared opioid dose reduction) (Elman et al., 2011 ).
However, it should be pointed out that there is an opposing literature noting that chronic pain patients are not more likely to abuse opioids, particularly when preexisting psychological states (i.e., depression and anxiety) are controlled for (Edlund et al., 2007; Elman et al., 2011; Fishbain et al., 1992) . Pain is thus associated with respective deficit and excess of reward, analgesia and stress. If deficits (sensory and emotional) can be corrected then individuals may be protected from addiction (Elman et al., 2011) . The same is true with regard to stress.
Pain and depression
Depressive symptoms are considered a key emotional component of chronic pain (Fishbain et al., 1997) and it is commonly hypothesized that such sequelae are mostly related to reduced motivation and anhedonia-like RD (Aguera-Ortiz et al., 2011; Nestler and Carlezon, 2006) . Consistent clinical findings of both subjective (Blackburn-Munro and Blackburn-Munro, 2001 ) and objective (Rouwette et al., 2012 ) stress markers in chronic pain patients call for the adaptation of this idea in the form of the CReAM, in other words, a state of dynamic interactions between RD and AR causing spiraling deterioration of both pain and reward function. Notably, patients with major depression, and no prior history of pain, commonly present pain symptoms. This suggests endogenous alterations in neural circuits resulting in the 'add on' phenotype (i.e., chronic pain). The figure shows the progressive changes that may occur in the evolution of chronic pain that include differences in process that involved in homeostatic, allostatic and allostatic load. (1) Under normal homeostatic conditions, there is a balanced interaction between circuitry involved in reward and aversion i.e., normal ability to like and dislike; (2) Under allostatic conditions (e.g., acute pain) there is a stressor that is mitigated by an opponent process (e.g., analgesics) that results in the normalization of the process i.e., pain −> pain relief; and (3) Under allostatic load, normative processes become disrupted such that antireward circuits dominate changes in brain processing in chronic pain that contribute to the maladaptive state in chronic pain (i.e., altered sensory processing and comorbid changes that may include depression, anxiety). Note that with the progression to chronic pain, there may be: (a) a diminished dopaminergic tone over time (i.e., hypodominergic condition) that contributes to a reward deficiency syndrome; and (b) increasing levels of chronic stress based on ongoing aversive condition.
Pain catastrophizing
Catastrophizing is an emotional state with a sense of impending doom or negative outcome that is predictive of pain intensity, disability and emotional distress (Edwards et al., 2006; Sullivan et al., 2001) . Pain catastrophizing is defined as a negative cognitive and emotional response to pain involving elements of rumination, magnification and feelings of helplessness (Quartana et al., 2009) . A number of experiential pain induction paradigms have found evoked responses and evoked connectivity that correlates to the degree of pain catastrophizing. The first study associating pain catastrophizing with brain functional responses (Gracely et al., 2004) in fibromyalgia patients has since been followed up by several investigations in both healthy subjects (Henderson et al., 2016; Seminowicz and Davis, 2006) and in clinical populations (Blankstein et al., 2010; Hubbard et al., 2014) , where the anterior insula, anterior cingulate, and thalamus were consistently found to correlate with pain catastrophizing. In women with chronic vulvar pain, catastrophizing correlated to parahippocampal and substantia nigra alterations (Schweinhardt et al., 2008) . Further, catastrophizing is associated with heightened reports of craving of opioid analgesics in patients with chronic pain (Martel et al., 2014) . There are, however, no studies to date directly linking pain catastrophizing and endogenous dopamine or opioid levels.
Avoidance behavior is a dynamic response that is not only influenced by pain and associated responding but also by contextual factors and competing goals such as obtaining a reward (Sheynin et al., 2015) . Reward sensitivity is a trait that predisposes to a variety of disinhibition disorders, including drug abuse and addiction (Volkow et al., 2010) . In chronic pain states, pain relief is a highly rewarding stimulus (Navratilova et al., 2015) , such that the goal to avoid pain may supersede patients' valued life goals. There may thus be a dual impact: persistent pain and stress reduce dopaminergic transmission (making pleasant things less pleasant), and by prioritizing pain avoidance over reward (for example not playing golf or not picking up a grandchild for fear of pain), patients may experience fewer rewarding situations altogether.
Treatment opportunities in CReAM
Consideration of CReAM may give rise to novel therapeutic strategies in chronic pain patients including pharmaco-and psycho-therapies, brain-training or a combination of these. Importantly, the chosen strategies certainly need to be tailored the nature of the pain condition with its severity and evolution (i.e., chronification). Innate differences in hedonic tone and responsivity may alter the magnitude of RD (Blum et al., 2012a) and AR.
Opioid ineffectiveness/resistance
The use of chronic opioids in chronic pain is not effective in all patients. In some conditions, including migraine, it may lead to disease chronification (Bigal and Lipton, 2009) , whereas in other conditions it may result in pain sensitization and/or addiction. Even when effective in chronic pain, the efficacy of analgesic drugs is rarely greater than 30% (Backonja et al., 1998) . One underlying reason may be the effects of chronic opioids on brain function and structure (Upadhyay et al., 2010) . But it might also be related to their effects on dopamine, contributing to RD or AR. Thus, analgesic therapy of the proponent pain stimuli could further deteriorate RD and AR and actually worsen rather than improve the pre-existing chronic pain condition. Changes in the mesolimbic dopaminergic circuitry induced by opioids, administered at doses exceeding the homeostatic need for pain alleviation, may be responsible for the amplification of "hyperkatifeia" or negative affective states and of physical pain itself (Elman et al., 2011; Shurman et al., 2010) . Hence, the rationale for the use of cognitive and behavioral strategies (e.g., cognitive restructuring, stress management and systemic desensitization) alongside non-addictive alternatives to opioids with substantial analgesic properties.
Pharmacotherapies for CReAM
Behaviorally, RD is characterized by anhedonia, numbing, apathy and decreased motivation for normally rewarding objects and goals. As such these processes are linked to diminished mesolimbic dopaminergic neurotransmission (Gardner, 2011; Solomon and Corbit, 1973) , which may be targets for psychopharmacological intervention (Gorelick et al., 2004; Schroeder et al., 2013) . Currently there are safe and non-addictive pharmaceutical agents that may restore dopaminergic function to improve RD-related symptoms. Proprietal is one example -an investigational nutraceutical that is composed of dopamine precursors with inhibitors of the dopamine-degrading enzyme catechol-O-methyl transferase. Such agents may provide therapeutic benefits for patients with RD Blum et al., 1988; Miller et al., 2010; Trachtenberg and Blum, 1988) .
Inasmuch as the within-system reward deficiency neuroadaptation mainly diminishes positive moods and motivations, the between systems anti-reward neuroadaptation amplified this effect via dynorphin on top of increasing negative affective states through the CRF and noradrenergic input (Koob and Le Moal, 1997 . These perturbations could be ameliorated by the pharmacological manipulation (not yet FDA approved) of kappa and CRF systems. Kappa antagonists that reportedly diminish stressinduced potentiation of drug reinforcement (McLaughlin et al., 2003) , have anti-depressant activity (Mague et al., 2003) and may inhibit the dynorphin-associated stress response (Land et al., 2008) . It should be noted, however, that while kappa agonists, have an antinociceptive effect, they also have negative side effects including dysphoria (Chavkin, 2011) . CRF receptor antagonists may also prove to be promising by diminishing the stress response (Bruijnzeel et al., 2010; Bruijnzeel et al., 2012; Carels and Shepherd, 1977) , which may also stabilize aberrant learning mechanisms. Elevations in stress hormones and neurotransmitters (e.g., cortisol) repeatedly paired with stressful situations can become conditioned cues and elicit aberrant behaviors and emotions (Elman et al., 2003) (e.g., drug seeking and catastrophizing). Anti-glutamatergic agents may be effective analgesics (e.g., benzodiazepine), however, these substances have a high potential for abuse. Indirect pharmacological manipulations of glutamatergic activity for pain relief in humans have been achieved with lamotrigine or topiramate (Wiffen et al., 2013) , as well as newer agents including minocycline (Kapoor, 2013) .
Stress is a strong candidate for cross-reactivity with pain (Gibson, 2012) . The neuroanatomical substrate for such an effect may involve two closely linked and interacting networks (viz., dopaminergic reward pathways and the extrahypothalamic norepinephrine/CRF system). As discussed above, alterations in the mesolimbic dopaminergic circuitry resulting from chronic pain may transform regular motivational processes into heightened incentive salience (see Box 1) assigned to pain and analgesia. Mesolimbic dopaminergic and extrahypothalamic norepinephrine/CRF systems are intimately linked; thus dopaminergic antagonists block norepinephrine/CRF anxiogenic responses and vice versa (Saigusa et al., 2012; Sommermeyer et al., 1995) . Adverse effects of typical anti-dopaminergic agents, which can be serious, may render them a less than optimal choice for the maintenance of patients with chronic pain. Nonetheless, the use of atypical antidopaminergics (acting on 5HT-2 and D2 receptors) may reverse the reward deficit state (Green et al., 1999) .
As noted above, part of AR relates to a hyper-noradrenergic profile. Noradrenaline increases pain facilitation (Martins et al., 2013) and drugs that inhibit noradrenaline may enhance anti-nociception (Burnham and Dickenson, 2013) . Descending inhibitory processes arise in multiple areas of the brain, including the anterior cingulate cortex, and project to brainstem regions involved in the modulation of pain (Jensen et al., 2009; Jensen et al., 2012; Mainero et al., 2011) . Thus, the rationale for the use of adrenergic antagonists relates to diminishing noradrenergic drive associated with AR that may produce, directly or indirectly, enhanced anti-nociception.
Brain modulation therapies for CReAM
Given that chronic pain may alter neural networks though CReAM-based changes, methods that counter these effects could contribute to symptomatic relief via adaptive plasticity (Karatsoreos and McEwen, 2011) . Brain regions such as the NAc or Hb are promising targets due to their significant interconnectivity with primary pain and reward circuitry. A salient example of this can be gleaned from reports on deep brain stimulation of the Hb in patients with apparently successful results in resistant depression (Schneider et al., 2013) . Unlike in the acute state, such stimulation is clearly altering both afferent and efferent pathways in a brain hub that connects forebrain to hindbrain (brainstem) structures (Hikosaka, 2010; Shelton et al., 2012) , many of which are involved in pain processing. Newer transcranial magnetic stimulation (TMS) techniques may offer the potential to carry out deep brain stimulation non-invasively (Spagnolo et al., 2013) .
Conclusions
Chronic pain is a major problem affecting millions of people around the world at the time when its predisposing factors, prevention strategies, etiology, pathophysiology and treatment are far from being fully elucidated. With this model considering the neurobiological overlap between pain processing and the reward and motivational circuitry, we considered the aspects of pain that are pertinent to the CReAM.
Pain chronification (see Box 1) certainly depends on the premorbid health of the relevant brain circuits (Baliki et al., 2012; Mansour et al., 2013) as well as maladaptive processing of RD and AR states. The combination of preclinical and clinical findings suggests that pain, by its chronic nature, leads to a hypodopaminergic condition in the reward circuitry, resulting in the diminution of the hedonic tone, viz., RD. At the same time, chronic pain patients become sensitized to stressful stimuli in conjunction with the AR markers of enhanced CRF, norepinephrine, dynorphin and glutamate (Elman et al., 2013) . This contributes to the build-up of the allostatic load Von Korff et al., 2009) and alters incentive salience of pain and analgesia, thus leading to catastrophizing, pseudo-addiction, pseudo-opioid resistance in conjunction with further worsening of anhedonia (Li et al., 2013) , depressive symptoms (Danna et al., 2013) and similar negative affective states arising in the context of the RD status. In connection with this, chronic pain may be conceptualized as a member of a potential group that may encompass other neuropsychiatric syndromes defined by the CReAM (e.g., addiction and major depression).
Thus our insights could have important implications for the primary and secondary prevention of chronification of pain. If neurobiological vulnerability factors can be identified, they might be used to screen patients at risk for the development of such condition. Patients found to possess high vulnerability for the development of chronic pain owing to preexisting diminution in reward and/or enhanced stress function might be counseled to avoid excessive drug and stress exposure (primary prevention), or targeted for early intervention even in the presence of mild pain problems (secondary prevention).
